Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Kath Kerry

- PMLiVE

UK, Germany back routine use of J&J’s Tremfya

The IL-23 inhibitor is currently being assessed in other EU countries

- PMLiVE

Revenue down the back of the beanbag

How to engage with employees to create a sophisticated strategy

Australian Flu and the dilemma of naming diseases

During the winter of 2017-2018 not a day passed when the Australian flu was not mentioned by the UK press. The British media turned talking about Australian flu into an...

Say Communications

- PMLiVE

Health Unlimited bolsters PR team

Appoints Ann Bartling as PR practice lead

- PMLiVE

Daily Brief: EULAR kicks off, Brexit lurches closer and Autolus prepares for IPO

A rapid round up of today's pharma, biotech and healthcare news

- PMLiVE

GSK’s vaccines president Debruyne heads for the exit

Roger Connor to take on the role in latest shake up

- PMLiVE

AbbVie builds case for arthritis blockbuster-in-waiting upadacitinib

Patients with RA reported an improvement in mobility pain on the JAK1 inhibitor

- PMLiVE

The Patient Journey

A roadmap for success

- PMLiVE

Jim Mellon’s biotech Juvenescence raises $50m for anti-ageing therapies

Billionaire's belief in emerging anti-ageing therapies fuels start up

- PMLiVE

Daily Brief: PRIME status for vaccine, NHS urged to adopt automation, Brexit votes loom

A rapid round up of pharma, biotech and healthcare news

- PMLiVE

Wearables and healthcare

What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?

IGNIFI

- PMLiVE

Gates’ non-profit biotech for poverty diseases sets out its stall at BIO

Chief executive Heaton says GatesMRI will be a place where translational science meets medicine

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links